2026.06.22

株主通信「SymBio VISION vol.29」(Japanese only)

2026.03.27

「動画で観るシンバイオ製薬」を更新しました。(Japanese only)

2026.03.27

第21期定時株主総会の動画を掲載しました。(Japanese only)

2026.03.17

SymBio Achieves First Patient In (FPI) in Global Phase 3 Clinical Trial of IV BCV for Adenovirus Infection Following Hematopoietic Stem Cell Transplantation

2026.02.19

SymBio Receives Notice of Patent Grant in the U.S. for IV BCV Use Patent, Securing Patent Exclusivity Through 2044

2026.02.13

2025年12月期決算説明会の動画を掲載しました。(Japanese only)

2026.02.10

決算説明会資料（2025年12月期）(Japanese only)

2026.02.02

SymBio Announces Cooperative Agreement with the NIH to Test IV Brincidofovir for Treating Progressive Multifocal Leukoencephalopathy

2026.01.29

A New Approach to Multiple Sclerosis Treatment Using IV BCV Research Results from a Collaborative Study with the U.S. NIH Published in the Journal of Clinical Investigation

2025.12.25

SymBio Announces Exclusive Global License Agreement with Tufts University for Treatment of Alzheimer’s Disease with IV BCV

2025.12.24

SymBio Announces Exclusive Global License Agreement with Penn State Research Foundation for Treatment of Polyomavirus Infections with IV BCV

2025.10.20

Patent Obtained for a Groundbreaking Immunoassay with Ultra-High Sensitivity (detection at one part in a trillion)

2025.10.06

SymBio Initiates Global Phase 3 Trial of IV Brincidofovir for the Treatment of Adenovirus Infection Post-HSCT, Following Regulatory Approval in Three Major European Countries

2023.05.29

IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial

2023.04.24

SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease

2023.03.22

Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)